Trellus Management Company LLC lifted its holdings in shares of Paratek Pharmaceuticals Inc (NASDAQ:PRTK) by 40.4% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 100,000 shares of the specialty pharmaceutical company’s stock after purchasing an additional 28,800 shares during the period. Trellus Management Company LLC owned about 0.31% of Paratek Pharmaceuticals worth $536,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of PRTK. Norges Bank purchased a new position in shares of Paratek Pharmaceuticals during the 4th quarter worth approximately $2,447,000. Fosun International Ltd purchased a new position in shares of Paratek Pharmaceuticals during the 4th quarter worth approximately $1,201,000. Dimensional Fund Advisors LP purchased a new position in shares of Paratek Pharmaceuticals during the 3rd quarter worth approximately $1,860,000. BlackRock Inc. increased its stake in shares of Paratek Pharmaceuticals by 3.6% during the 3rd quarter. BlackRock Inc. now owns 2,677,154 shares of the specialty pharmaceutical company’s stock worth $25,967,000 after purchasing an additional 93,764 shares in the last quarter. Finally, Teton Advisors Inc. increased its stake in shares of Paratek Pharmaceuticals by 350.0% during the 4th quarter. Teton Advisors Inc. now owns 108,000 shares of the specialty pharmaceutical company’s stock worth $554,000 after purchasing an additional 84,000 shares in the last quarter. 74.30% of the stock is owned by institutional investors and hedge funds.

Shares of PRTK traded up $0.27 during mid-day trading on Tuesday, reaching $5.70. The company had a trading volume of 353,658 shares, compared to its average volume of 303,414. The firm has a market cap of $176.02 million, a PE ratio of -1.60 and a beta of 1.52. Paratek Pharmaceuticals Inc has a fifty-two week low of $4.50 and a fifty-two week high of $12.30. The company has a quick ratio of 14.41, a current ratio of 14.41 and a debt-to-equity ratio of 4.81.

Paratek Pharmaceuticals (NASDAQ:PRTK) last announced its quarterly earnings results on Wednesday, February 27th. The specialty pharmaceutical company reported ($0.71) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.65) by ($0.06). The company had revenue of $17.02 million during the quarter, compared to analyst estimates of $16.50 million. Paratek Pharmaceuticals had a negative net margin of 656.41% and a negative return on equity of 149.09%. As a group, equities research analysts anticipate that Paratek Pharmaceuticals Inc will post -4.38 earnings per share for the current year.

A number of brokerages have recently weighed in on PRTK. Zacks Investment Research raised shares of Paratek Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, February 14th. HC Wainwright reissued a “buy” rating on shares of Paratek Pharmaceuticals in a research note on Thursday, February 28th. Canaccord Genuity lifted their target price on shares of Paratek Pharmaceuticals from $14.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, January 16th. LADENBURG THALM/SH SH set a $18.00 price target on shares of Paratek Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, February 28th. Finally, ValuEngine upgraded shares of Paratek Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, April 1st. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. Paratek Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $23.25.

ILLEGAL ACTIVITY WARNING: This story was first reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://www.watchlistnews.com/paratek-pharmaceuticals-inc-prtk-shares-bought-by-trellus-management-company-llc/2982761.html.

Paratek Pharmaceuticals Profile

Paratek Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon biology and tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.

Featured Story: What is the Dividend Aristocrat Index?

Want to see what other hedge funds are holding PRTK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Paratek Pharmaceuticals Inc (NASDAQ:PRTK).

Institutional Ownership by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.